ClinicalTrials.gg
RecruitingNCT06921785ARTEMIDE-HCC01Updated Oct 13, 2026

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

A Phase 3 interventional study of Tremelimumab and Rilvegostomig in Hepatocellular Carcinoma, sponsored by AstraZeneca. Recruiting at 226 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 13, 2026Site recruiting status changed8 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing tremelimumab in Carcinoma, Hepatocellular — 15 open to participants now, 28 under way, 5 of them phase 3. tremelimumab · Carcinoma, Hepatocellular.

Planned enrollment
2nd of 34
1,220 · median 35
Started
2025
with 6 others
Phase 3
5 of 34
2 open now
Primary completion
2030-03
later than 25 of 27 live
Registered
27th of 34
by date
Lead sponsor
5 of 34
AstraZeneca

Among the 34 studies testing tremelimumab in Carcinoma, Hepatocellular, this one is the 2nd largest by planned enrollment, is one of 7 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 25 of the 27 other live ones, and was the 27th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

15 of the 34 studies testing tremelimumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing tremelimumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Read the detailed description

The purpose of this study is to assess the efficacy and tolerability of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line treatment in participants with advanced HCC. The study comprises 2 parts - a safety lead-in and a randomised period. Prior to the start of the randomised period of the study, a single-arm safety lead-in period will be applied to evaluate the safety and tolerability of rilvegostomig in combination with bevacizumab and tremelimumab.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or and/or unresectable HCC
  • performance status of 0 or 1
  • BCLC stage B (that is not eligible for locoregional therapy) or stage C.
  • Score class A
  • At least one measurable target lesion
  • Participants with active infection must receive antiviral therapy for a minimum of 14 days prior to randomization to show evidence of HBV stabilization or signs of viral response.
  • Participants with active infection must be well controlled. Participants co-infected with HBV and HCV are not eligible.
  • Adequate organ and bone marrow function measured during the screening period.
  • Adequate organ and bone marrow function measured during the screening period
  • Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.
  • Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.

Exclusion criteria

Exclusion Criteria:

Medical condition

  • Any evidence of uncontrolled intercurrent diseases
  • Active or prior documented or inflammatory disorders requiring chronic treatment with or other treatment
  • History of another primary
  • Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
  • ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose.
  • History of active primary immunodeficiency or active infection
  • History of hepatic encephalopathy
  • Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol
  • Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible
  • History of significant bleeding disorders, vasculitis, or a significant bleeding episode from the GI tract within 6 months prior to study randomization.
  • Participants with untreated or incompletely treated varices with bleeding or high-risk (red wale signs or other high-risk factors) for bleeding.

HCC related

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • Central nervous system or spinal cord compression (including asymptomatic and adequately treated disease)
  • Prior treatment with and/or anti-TIGIT.
  • Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,220 participants (estimated)

Study arms

  • Experimental
    Arm A

    Tremelimumab , rilvegostomig and bevacizumab

    Drug: Tremelimumab · Drug: Rilvegostomig · Drug: Bevacizumab

  • Experimental
    Arm B

    Rilvegostomig, and bevacizumab

    Drug: Rilvegostomig · Drug: Bevacizumab

  • Active comparator
    Arm C

    Atezolizumab, and bevacizumab

    Drug: Bevacizumab · Drug: Atezolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 6 years

Secondary outcomes

  1. To demonstrate the efficacy of Arm B relative to Arm C by assessment of OS in participants with advanced HCC

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 6 years

  2. To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC

    PFS according to RECIST 1.1

    Time frame: Up to approximately 6 years

  3. To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC

    ORR according to RECIST 1.1

    Time frame: Up to approximately 6 years

  4. To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relative to Arm C in participants with advanced HCC

    DoR according to RECIST 1.1

    Time frame: Up to approximately 6 years

  5. To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC

    OS

    Time frame: Up to approximately 6 years

  6. To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC

    PFS

    Time frame: Up to approximately 6 years

  7. To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC

    ORR

    Time frame: Up to approximately 6 years

  8. To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC

    DoR

    Time frame: Up to approximately 6 years

  9. To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups

    Association of PD-L1 expression level with: • OS

    Time frame: Up to approximately 6 years

  10. To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups

    Association of PD-L1 expression level with: • PFS per RECIST 1.1

    Time frame: Up to approximately 6 years

  11. To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups

    Association of PD-L1 expression level with: • ORR per RECIST 1.1

    Time frame: Up to approximately 6 years

  12. To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups

    Association of PD-L1 expression level with: OS

    Time frame: Up to approximately 6 years

  13. To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups

    Association of PD-L1 expression level with: PFS per RECIST 1.1

    Time frame: Up to approximately 6 years

  14. To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups

    Association of PD-L1 expression level with: ORR per RECIST 1.1

    Time frame: Up to approximately 6 years

  15. To investigate the immunogenicity of Arm A and Arm B

    Presence of ADAs for tremelimumab and rilvegostomig

    Time frame: Up to approximately 6 years

  16. Occurrence of adverse events (AEs) and serious adverse events (SAEs)

    Occurrence of AEs and SAEs will be graded according to the revised NCI CTCAE v5.0.

    Time frame: Up to approximately 6 years

07

Study locations

189 of 226 sites recruiting
  • Research Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Research Site
    Tucson, Arizona 85719, United States
    Recruiting
  • Research Site
    Los Angeles, California 90095, United States
    Recruiting
  • Research Site
    Palo Alto, California 94304, United States
    Recruiting
  • Research Site
    Denver, Colorado 80210, United States
    Not yet recruiting
  • Research Site
    New Haven, Connecticut 06520, United States
    Recruiting
  • Research Site
    Newark, Delaware 19713, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Research Site
    Orlando, Florida 32804, United States
    Not yet recruiting
  • Research Site
    Atlanta, Georgia 30318, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Honolulu, Hawaii 96813, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Research Site
    Indianapolis, Indiana 46202, United States
    Not yet recruiting
  • Research Site
    Shreveport, Louisiana 71103, United States
    Not yet recruiting
  • Research Site
    Detroit, Michigan 48202, United States
    Recruiting
  • Research Site
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63108, United States
    Not yet recruiting
  • Research Site
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Research Site
    New York, New York 10029, United States
    Recruiting
  • Research Site
    New York, New York 10032, United States
    Recruiting
  • Research Site
    New York, New York 10065, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Oklahoma City, Oklahoma 73104, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Research Site
    Amarillo, Texas 79124, United States
    Recruiting
  • Research Site
    Austin, Texas 78705, United States
    Recruiting
  • Research Site
    Dallas, Texas 75390, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78240, United States
    Recruiting
  • Research Site
    Tyler, Texas 75702, United States
    Recruiting
  • Research Site
    Arlington, Virginia 22201, United States
    Recruiting
  • Research Site
    Salem, Virginia 24153, United States
    Recruiting
  • Research Site
    Seattle, Washington 98101, United States
    Recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Research Site
    Camperdown, 2050, Australia
    Recruiting
  • Research Site
    Clayton, 3168, Australia
    Recruiting
  • Research Site
    Heidelberg, 3084, Australia
    Recruiting
  • Research Site
    Randwick, 2031, Australia
    Recruiting
  • Research Site
    South Brisbane, 4101, Australia
    Recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 91350-200, Brazil
    Recruiting
  • Research Site
    Santa Maria, 97015-450, Brazil
    Recruiting
  • Research Site
    São Paulo, 04014-002, Brazil
    Recruiting
  • Research Site
    São Paulo, 05652-9000, Brazil
    Recruiting
  • Research Site
    Vitória, 29043-272, Brazil
    Recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
    Not yet recruiting
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
    Recruiting
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
    Recruiting
  • Research Site
    Cambridge, Ontario N1R 3G2, Canada
    Not yet recruiting
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Toronto, Ontario M5G 1X6, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
    Recruiting
  • Research Site
    Beijing, 100034, China
    Recruiting
  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Beijing, CN-100730, China
    Recruiting
  • Research Site
    Changchun, 130021, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chifeng, 024000, China
    Recruiting
  • Research Site
    Chongqing, 400010, China
    Recruiting
  • Research Site
    Deyang, 618000, China
    Recruiting
  • Research Site
    Fuzhou, 350005, China
    Recruiting
  • Research Site
    Guangzhou, 510060, China
    Recruiting
  • Research Site
    Guangzhou, 510515, China
    Recruiting
  • Research Site
    Guiyang, 550002, China
    Recruiting
  • Research Site
    Harbin, 150081, China
    Recruiting
  • Research Site
    Hefei, 230022, China
    Recruiting
  • Research Site
    Hohhot, 010020, China
    Recruiting
  • Research Site
    Kunming, 650118, China
    Not yet recruiting
  • Research Site
    Linyi, 276000, China
    Recruiting
  • Research Site
    Lishui, 323000, China
    Recruiting
  • Research Site
    Luoyang, 471000, China
    Recruiting
  • Research Site
    Nanchang, 330008, China
    Recruiting
  • Research Site
    Nanchang, 330029, China
    Recruiting
  • Research Site
    Nanjing, 210029, China
    Recruiting
  • Research Site
    Nanning, 530021, China
    Recruiting
  • Research Site
    Nantong, 226361, China
    Recruiting
  • Research Site
    Neijiang, 641100, China
    Recruiting
  • Research Site
    Shandong, China
    Recruiting
  • Research Site
    Shanghai, 201114, China
    Recruiting
  • Research Site
    Shenyang, 110004, China
    Recruiting
  • Research Site
    Shenyang, 110042, China
    Recruiting
  • Research Site
    Weifang, 261000, China
    Recruiting
  • Research Site
    Wenzhou, 325000, China
    Recruiting
  • Research Site
    Wuhan, 430079, China
    Recruiting
  • Research Site
    Xi'an, 710100, China
    Recruiting
  • Research Site
    Zhengzhou, 450008, China
    Recruiting
  • Research Site
    Clichy, 92118, France
    Recruiting
  • Research Site
    Lille, 59000, France
    Recruiting
  • Research Site
    Lyon, 69317, France
    Recruiting
  • Research Site
    Montpellier, 34090, France
    Recruiting
  • Research Site
    Nantes, 44093, France
    Recruiting
  • Research Site
    Nice, 06200, France
    Recruiting
  • Research Site
    Pessac, 33604, France
    Recruiting
  • Research Site
    Rennes, 35000, France
    Recruiting

Showing the first 100 of 226 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individualpatient-level data from AstraZeneca group of companies sponsoredclinical trials via the request portal Vivli.org. All requests will be evaluatedas per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does notmean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitmentsmade to the EFPIA PhRMA Data Sharing Principles. For details of ourtimelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to theanonymized individual patient-level data via secure research environmentVivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2030, 58 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's planned 58 months is close to that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 10, 2025
StartActual
May 6, 2025
Primary completionEst.
Mar 15, 2030
CompletionEst.
Mar 15, 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 1 site removed. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • Research Site · Clayton, AustraliaNot yet recruiting→Recruiting
  • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
  • Research Site · Shenyang, ChinaNot yet recruiting→Recruiting
  • Research Site · Montpellier, FranceNot yet recruiting→Recruiting
  • Research Site · Mumbai, IndiaNot yet recruiting→Recruiting
  • Research Site · Nashik, IndiaNot yet recruiting→Recruiting
  • Research Site · Utrecht, NetherlandsSuspended→Recruiting
  • Research Site · Cambridge, United KingdomNot yet recruiting→Recruiting
Show 8 added (4 Germany, 1 United States, 1 Australia, 1 Poland, 1 Turkey (Türkiye))
  • Research Site · Denver, United States
  • Research Site · South Brisbane, Australia
  • Research Site · Chemnitz, Germany
  • Research Site · Cologne, Germany
  • Research Site · Erlangen, Germany
  • Research Site · Munich, Germany
  • Research Site · Bydgoszcz, Poland
  • Research Site · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Research Site · Auchenflower, Australia
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    8 sites added, 1 site removed. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • Research Site · Clayton, AustraliaNot yet recruiting→Recruiting
    • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
    • Research Site · Shenyang, ChinaNot yet recruiting→Recruiting
    • Research Site · Montpellier, FranceNot yet recruiting→Recruiting
    • Research Site · Mumbai, IndiaNot yet recruiting→Recruiting
    • Research Site · Nashik, IndiaNot yet recruiting→Recruiting
    • Research Site · Utrecht, NetherlandsSuspended→Recruiting
    • Research Site · Cambridge, United KingdomNot yet recruiting→Recruiting
    Show 8 added (4 Germany, 1 United States, 1 Australia, 1 Poland, 1 Turkey (Türkiye))
    • Research Site · Denver, United States
    • Research Site · South Brisbane, Australia
    • Research Site · Chemnitz, Germany
    • Research Site · Cologne, Germany
    • Research Site · Erlangen, Germany
    • Research Site · Munich, Germany
    • Research Site · Bydgoszcz, Poland
    • Research Site · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Research Site · Auchenflower, Australia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06921785
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
May 6, 2025
Primary completion
Mar 15, 2030 (estimated)
Completion
Mar 15, 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tremelimumab · Rilvegostomig

Start the discussion